Study to investigate changes in airway inflammation, symptoms, and rescue therapy utilization with AIRSUPRA compared to albuterol as needed in adults with mild asthma - DARWIN

Study identifier:D6930C00018

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A 12-week, Randomized, Double-Blind, Phase 4 Study Evaluating the Effect of AIRSUPRA Compared to Albuterol Administered as Needed on Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization in Adults with Mild Asthma

Medical condition

Mild Asthma

Phase

Phase 4

Healthy volunteers

No

Study drug

Albuterol/Budesonide, Albuterol

Sex

All

Estimated Enrollment

100

Study type

Interventional

Age

18 Years - 120 Years

Date

Study Start Date: 13 Sept 2024
Estimated Primary Completion Date: 10 Nov 2025
Estimated Study Completion Date: 10 Nov 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Fortrea

Inclusion and exclusion criteria